Cargando…
Cancer Drug Response Profile scan (CDRscan): A Deep Learning Model That Predicts Drug Effectiveness from Cancer Genomic Signature
In the era of precision medicine, cancer therapy can be tailored to an individual patient based on the genomic profile of a tumour. Despite the ever-increasing abundance of cancer genomic data, linking mutation profiles to drug efficacy remains a challenge. Herein, we report Cancer Drug Response pro...
Autores principales: | Chang, Yoosup, Park, Hyejin, Yang, Hyun-Jin, Lee, Seungju, Lee, Kwee-Yum, Kim, Tae Soon, Jung, Jongsun, Shin, Jae-Min |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996063/ https://www.ncbi.nlm.nih.gov/pubmed/29891981 http://dx.doi.org/10.1038/s41598-018-27214-6 |
Ejemplares similares
-
Lipid-lowering drug adherence and combination therapy effects on gastrointestinal cancer in patients with dyslipidemia without diabetes: a retrospective cohort study in South Korea
por: Han, Kyu-Tae, et al.
Publicado: (2022) -
Predicting Drug Resistance Using Deep Mutational Scanning
por: Pines, Gur, et al.
Publicado: (2020) -
Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures
por: Lee, Haeseung, et al.
Publicado: (2016) -
Unique Behavioral Characteristics and microRNA Signatures in a Drug Resistant Epilepsy Model
por: Moon, Jangsup, et al.
Publicado: (2014) -
Regional and income disparities in treatment and drug adherence of patients with dyslipidemia: a retrospective cohort study in South Korea, 2003–2015
por: Han, Kyu-Tae, et al.
Publicado: (2021)